Full metadata record
DC FieldValueLanguage
dc.creatorAshton, N.J. (Nicholas J.)-
dc.creatorSuárez-Calvet, M. (Marc)-
dc.creatorHeslegrave, A. (Amanda)-
dc.creatorHye, A. (Abdul)-
dc.creatorRazquin, C. (Cristina)-
dc.creatorPastor, P. (Pau)-
dc.creatorSanchez-Valle, R. (Raquel)-
dc.creatorMolinuevo, J.L. (José L.)-
dc.creatorJelle-Visser, P. (Pieter)-
dc.creatorBlennow, K. (Kaj)-
dc.creatorHodges, A.K. (Angela K.)-
dc.creatorZetterberg, H. (Henrik)-
dc.identifier.citationAshton, N.J. (Nicholas J.); Suárez-Calvet, M. (Marc); Heslegrave, A. (Amanda); et al. "Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers". Alzheimer's Research & Therapy. 11 (94), 2019, 2019es
dc.description.abstractBackground: Results from recent clinical studies suggest that cerebrospinal fluid (CSF) biomarkers that are indicative of Alzheimer’s disease (AD) can be replicated in blood, e.g. amyloid-beta peptides (Aβ42 and Aβ40) and neurofilament light chain (NFL). Such data proposes that blood is a rich source of potential biomarkers reflecting central nervous system pathophysiology and should be fully explored for biomarkers that show promise in CSF. Recently, soluble fragments of the triggering receptor expressed on myeloid cells 2 (sTREM2) protein in CSF have been reported to be increased in prodromal AD and also in individuals with TREM2 rare genetic variants that increase the likelihood of developing dementia. Methods: In this study, we measured the levels of plasma sTREM2 and plasma NFL using the MesoScale Discovery and single molecule array platforms, respectively, in 48 confirmed TREM2 rare variant carriers and 49 non-carriers. Results: Our results indicate that there are no changes in plasma sTREM2 and NFL concentrations between TREM2 rare variant carriers and non-carriers. Furthermore, plasma sTREM2 is not different between healthy controls, mild cognitive impairment (MCI) or AD. Conclusion: Concentrations of plasma sTREM2 do not mimic the recent changes found in CSF sTREM2.es_ES
dc.description.sponsorshipThe study has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 115976. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and EFPIA (AKH and HZ), the UK Dementia Research Institute (AKH and HZ) and the Olav Thon Foundation. This study is an independent research partly funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. NFL measurements were performed on equipment purchased through a Wellcome Trust Multi-User Equipment Grant. The plasma samples were collected with funding through the EU FP6 programme (AddNeuroMed).es_ES
dc.publisherSpringer Science and Business Media LLCes_ES
dc.subjectAlzheimer’s diseasees_ES
dc.subjectNeurofilament light chaines_ES
dc.titlePlasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carrierses_ES
dc.description.noteThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.es_ES
dadun.citation.publicationNameAlzheimer's Research & Therapyes_ES

Files in This Item:
686.69 kB
Adobe PDF

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.